Tower Research Capital (TRC)’s BioNexus Gene Lab BGLC Stock Holding History
Bought
Maintained
Sold
Other funds holding BGLC
Tower Research Capital (TRC)'s BGLC Position: Q3 2026 in Review
Tower Research Capital (TRC) opened a new position in BioNexus Gene Lab (BGLC) in Q3 2026: 12 shares worth $15. The stake represents ﹤0.01% of the portfolio and ranks #5835 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in BGLC as recently as Q4 2023.
Tower Research Capital (TRC) first reported a position in BGLC in Q4 2023 and has held it in 2 quarters since. The position peaked at $3.09K in Q4 2023. 4 funds tracked by Wall St. Rank hold BGLC as of Q3 2026.
- Tower Research Capital (TRC) held 12 shares of BioNexus Gene Lab worth $15 as of Q3 2026.
- BioNexus Gene Lab was a new Tower Research Capital (TRC) position in Q3 2026.
- BioNexus Gene Lab made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q3 2026, its #5835 holding.
- Tower Research Capital (TRC) first reported a position in BioNexus Gene Lab in Q4 2023 and has held it in 2 quarters since.
- Tower Research Capital (TRC)'s BioNexus Gene Lab position peaked at $3.09K in Q4 2023.
- 4 funds tracked by Wall St. Rank held BioNexus Gene Lab as of Q3 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q3 2026, filed 16 Nov 2026.